De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sofiva GenomicsLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Sofiva GenomicsLtd heeft een totaal eigen vermogen van NT$640.7M en een totale schuld van NT$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk NT$775.8M en NT$135.1M. De EBIT Sofiva GenomicsLtd is NT$2.2M waardoor de rentedekking -9.4 is. Het heeft contanten en kortetermijnbeleggingen van NT$123.4M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

NT$0

Schuld

Rente dekkingsratio	-9.4x
Contant	NT$123.42m
Aandelen	NT$640.72m
Totaal verplichtingen	NT$135.13m
Totaal activa	NT$775.84m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Apr 14

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Mar 18

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Feb 24

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 27

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$281.0M ) 6615 } overtreffen de korte termijn passiva ( NT$89.6M ).

Langlopende schulden: De kortetermijnactiva 6615 ( NT$281.0M ) overtreffen de langetermijnschulden ( NT$45.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 6615 is schuldenvrij.

Schuld verminderen: 6615 had 5 jaar geleden geen schulden.

Schuldendekking: 6615 heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: 6615 heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Sofiva GenomicsLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.45 (vs NT$0.20 in 2Q 2023)

Sofiva Genomics Co.,Ltd. to Report Q2, 2024 Results on Aug 14, 2024

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 17%

Upcoming dividend of NT$0.20 per share

Dividend reduced to NT$0.20

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.20 in 1Q 2023)

Sofiva Genomics Co.,Ltd. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profit margin trend

Sofiva Genomics Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$0.27 (vs NT$0.12 in 3Q 2022)

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Sofiva Genomics Co.,Ltd. Announces Resignation of Su,Yining as CEO

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.28 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Upcoming dividend of NT$1.00 per share at 2.5% yield

Sofiva Genomics Co.,Ltd. Declares Cash Dividend, Payable on July 31, 2023

Investor sentiment improves as stock rises 23%

Full year 2022 earnings released: EPS: NT$2.00 (vs NT$2.68 in FY 2021)

Less than half of directors are independent

Second quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of NT$2.00 per share

Sofiva Genomics Co.,Ltd. Announces Cash Dividend, Payable on July 28, 2022

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.68 (vs NT$0.28 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.40 in 2Q 2020)

Upcoming dividend of NT$1.40 per share

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.49 in 1Q 2020)

Investor sentiment improved over the past week

Some Investors May Be Worried About Sofiva GenomicsLtd's (GTSM:6615) Returns On Capital

Full year 2020 earnings released: EPS NT$1.63 (vs NT$2.96 in FY 2019)

Estimating The Fair Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

Sofiva Genomics Co.,Ltd. (GTSM:6615) Investors Should Think About This Before Buying It For Its Dividend

Should Weakness in Sofiva Genomics Co.,Ltd.'s (GTSM:6615) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$50.60

Our Take On The Returns On Capital At Sofiva GenomicsLtd (GTSM:6615)

New 90-day low: NT$51.60

A Look At The Intrinsic Value Of Sofiva Genomics Co.,Ltd. (GTSM:6615)

New 90-day low: NT$54.00

Read This Before Buying Sofiva Genomics Co.,Ltd. (GTSM:6615) For Its Dividend

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day low: NT$55.00

New 90-day low - NT$55.20

New 90-day low - NT$59.00

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven